

# Improving detection of associations between congenital anomalies and medicines taken in the first trimester of pregnancy, using data derived hierarchies.

**First published:** 22/09/2022

**Last updated:** 22/09/2022

Study

Planned

## Administrative details

### EU PAS number

EUPAS49055

---

### Study ID

49056

---

### DARWIN EU® study

No

---

### Study countries

☐ Belgium

☐ Denmark

☐ France

- ☐ Ireland
  - ☐ Italy
  - ☐ Malta
  - ☐ Netherlands
  - ☐ Norway
  - ☐ Poland
  - ☐ Switzerland
  - ☐ United Kingdom
- 

### **Study description**

Identification of signals of potential harm is an important aspect of drug safety monitoring after regulatory approval. Current signal detection methods focus on the increased occurrence of single defects, but many teratogenic medications result in multiple defects. Different medications may also have similar patterns of associations with specific defects. Statistical methods to simultaneously analyse data on several birth defects and several medications within the EUROMediCAT database have been developed. These methods will be tested on EUROMediCAT data and results will be evaluated and interpreted by an advisory committee consisting of clinical specialists, pharmacologists and geneticist.

---

### **Study status**

Planned

## Research institutions and networks

### Institutions

# St George's University of London

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Networks

EUROmediCAT

## Contact details

### Study institution contact

Joan Morris [jmorris@sgul.ac.uk](mailto:jmorris@sgul.ac.uk)

Study contact

[jmorris@sgul.ac.uk](mailto:jmorris@sgul.ac.uk)

### Primary lead investigator

Joan Morris

Primary lead investigator

## Study timelines

**Date when funding contract was signed**

Planned: 01/10/2021

Actual: 01/10/2021

---

### **Study start date**

Planned: 01/10/2022

---

### **Date of final study report**

Planned: 01/09/2024

## Sources of funding

- Other

## More details on funding

Medical Research Council (MRC)

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Other

**If 'other', further details on the scope of the study**

Methodological

**Main study objective:**

Does the identification of groups of anomalies with similar patterns of association across several medications, and identification of groups of medications with similar patterns of association across several anomalies, improve signal detection of teratogens within the EUROmediCAT database?

## Study Design

**Non-interventional study design**

Other

---

**Non-interventional study design, other**

Case-only

## Population studied

**Age groups**

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

---

## **Special population of interest**

Pregnant women

---

## **Estimated number of subjects**

33000

# Study design details

## **Data analysis plan**

Suitable statistical methods to simultaneously analyse data on multiple birth defects and multiple medications within the EUROmediCAT database have been developed by searching the literature for application of similar methods in other fields of research and adapting such methods. An advisory committee containing specialists, pharmacologists and geneticists has been created to assist in model selection and interpretation of results. Chosen methods will be applied initially to a drug and anomaly blinded EUROmediCAT database, with additional information from the EUROCAT database incorporated into models where appropriate. Final model selection will be supported by the advisory team based on the simulation performance and blinded results. The chosen model(s) will then be applied to data from the EUROmediCAT and EUROCAT databases. The advisory committee will assist and support the interpretation of results, including assimilation of new signals with known teratogens.

## Data management

## Data sources

**Data source(s)**

EUROmediCAT central database

---

**Data sources (types)**

[Disease registry](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No